[62], who documented objective responses (including decreased cellularity and stromal hyalinization) to larotrectinib in pediatric mesenchymal tumors harboring TPM3‐NTRK1 fusions, and Huang et al. The gene discussed is TPM3; the disease is mesenchymal cell neoplasm.